Update
$BioCryst Pharmaceuticals (BCRX.US)$ BioCryst Pharmaceuticals Says New Analyses Of Real-world Use Of Oral, Once-daily Orladeyo (Berotralstat) Showed Patients Who Initiated Orladeyo Experienced Rapid, Substantial And Sustained Reductions In Attack Rates Through 18 Months Of Treatment
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Kevin Matte : finally i bought it today ^^
Trytosaveabit OP Kevin Matte : GL and big profits to ya! I’m still waiting a bit to see if seems to be at bottom!